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Lasse Karhu, Ainoleena Turku and Henri Xhaard*Abstract
Background: Interactions between the orexin peptides and their cognate OX1 and OX2 receptors remain poorly
characterized. Site-directed mutagenesis studies on orexin peptides and receptors have indicated amino acids
important for ligand binding and receptor activation. However, a better understanding of specific pairwise
interactions would benefit small molecule discovery.
Results: We constructed a set of three-dimensional models of the orexin 1 receptor based on the 3D-structures of
the orexin 2 receptor (released while this manuscript was under review), neurotensin receptor 1 and chemokine
receptor CXCR4, conducted an exhaustive docking of orexin-A16–33 peptide fragment with ZDOCK and RDOCK, and
analyzed a total of 4301 complexes through multidimensional scaling and clustering. The best docking poses reveal
two alternative binding modes, where the C-terminus of the peptide lies deep in the binding pocket, on average
about 5–6 Å above Tyr6.48 and close to Gln3.32. The binding modes differ in the about 100° rotation of the peptide;
the peptide His26 faces either the receptor’s fifth transmembrane helix or the seventh helix. Both binding modes
are well in line with previous mutation studies and partake in hydrogen bonding similar to suvorexant.
Conclusions: We present two binding modes for orexin-A into orexin 1 receptor, which help rationalize previous
results from site-directed mutagenesis studies. The binding modes should serve small molecule discovery, and offer
insights into the mechanism of receptor activation.
Keywords: Orexin-A, OX1 receptor, Peptide docking, G protein-coupled receptor, Pose selection, Multidimensional
scaling, GPCRBackground
The orexinergic system is composed of two receptor
subtypes, named orexin 1 and 2 receptors (OX1R and
OX2R respectively), and of two agonistic peptide ligands,
orexin-A and orexin-B [1]. Orexin receptors are mainly
found in the central nervous system, but also in the per-
iphery (gastrointestinal track, pancreas, adrenal gland
and adipose tissue) [2]. Certain cancer cell lines also ex-
press OX1 receptors, whose activation induces apoptosis
[3]. The endogenous orexin peptides induce feeding and
wakefulness, and malfunctions of the orexin system are
one of the reasons behind narcolepsy in mice, dogs and
humans [2]. Small molecules (i.e. not peptides) have
been developed to act as orexin receptor antagonists [4].
As expected, antagonists have opposing effects to orexin
peptides; reduced feeding [5] and induction of sleep [4].* Correspondence: henri.xhaard@helsinki.fi
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creativecommons.org/publicdomain/zero/1.0/The first drug targeting the orexin receptors, the antag-
onist suvorexant (Belsomra®), has recently reached the
market in the United States of America and in Japan.
Orexin peptides and receptors were discovered inde-
pendently in 1998 by two research groups. Sakurai and
co-workers discovered two peptides that produced ro-
bust Ca2+ elevation through activation of two receptors
which they expressed in CHO cells [1]. The two peptides
were named orexin-A and -B, and the receptor subtypes
were designated as OX1 and OX2 receptors according to
the Greek word for appetite, oreksis (ὄρεξις), since the
peptides induced feeding in mice. De Lecea and co-
workers discovered about simultaneously a mRNA
sequence expressed in hypothalamus that encodes the
precursor of the two peptides [6]. They named the
peptides hypocretins 1 and 2.
The orexin peptides are produced as a 131-amino
acid (in human) precursor, prepro-orexin, which is enzy-
matically cleaved to produce one unit of each peptide [1].icle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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two intramolecular disulfide bridges (Cys6–Cys12, Cys7–
Cys14), an N-terminal pyroglutamoyl residue, and an ami-
dated C-terminus [1]. Human orexin-B is composed of 28
residues and is amidated on its C-terminus like orexin-A,
but lacks the disulfide bridges [1]. While the N-termini of
the peptides are different, the C-termini are near-identical
(11 out of 15 amino acids are identical). The receptor-
bound conformations are not known, but NMR-structures
for both peptides in buffered water solution have been
solved [7,8]. Orexin-B comprises two helical parts (helix I:
Leu7–Gly19 and helix II: Ala23–Met28) joined with a
short linker or hinge (Asn20–Ala22) [7], whereas orexin-
A has three helical sections (helix I: Leu16–Ala23, helix II:
Asn25–Thr32 and helix III: Cys6–Gln9) [8]. The peptides
were observed in multiple conformations: orexin-A is
either in bent or straight conformation across the set of 30
NMR models [8], while the single model derived for
orexin-B shows the hinge bent opposite to the conform-
ation of orexin-A [7] (Additional file 1).
Mutations on the orexin peptides have shown that the
C-terminal residues and the amidation of the C-
terminus are the most important factors for receptor ac-
tivation [9-12]. The N-terminus is not as important, as
both peptides retained activity when truncated down to
a C-terminal fragment of 19 residues [9-11]. Further
truncation lowered the maximal response, but fragments
as short as 12 amino acids still retained some activity
[9-11]. No key residues have been found in the N-
terminal part of the peptide.
The orexin receptors OX1R and OX2R are G protein-
coupled receptors (GPCRs) that in human are composed
of 425 amino acids (OX1R) and 444 amino acids (OX2R)
[1]. As GPCRs, the overall structure of orexin receptors
consists of seven helical transmembrane segments
(TM1–7) connected by three intra- and three extracellular
loops (ICL1–3 and ECL1–3 respectively), an extracellular
N-terminus and an intracellular C-terminus, confirmed
by the recent crystal structure of OX2R [PDB:4S0V]
[13] that was solved while this manuscript was under
review. The OX2 receptor has the conserved disulfide
bridge connecting TM3 and ECL2, as was expected
based on the receptor sequences. Most likely the OX1R
will also have this bridge formed by Cys1193.25 and
Cys202xl2.50.a Both receptors have also suitable cyste-
ines for C-terminal palmitoylation (Cys375 and Cys376
in OX1R), which is observed in most crystallized
GPCRs. The human OX1R and OX2R share a full-
length pairwise sequence identity of 64%, and without
terminals and ICL3, the sequence identity of the TM
bundle is up to 80%. Orexin-A is equipotent towards
both receptor subtypes, whereas orexin-B is equipotent
with orexin-A towards OX2R but 10-fold less potent in
activating OX1R [10,11].The receptors have been mutated [14,15] and chimeras
of OX1R and OX2R have been constructed [15,16] to
study the contributions of different amino acids to inter-
actions with ligands (Figure 1). Alanine mutations of
OX1R residues Gln126
3.32, Val1303.36, Asp203xl2.51,
Trp206xl2.54, Tyr2155.38, Phe2195.42, Tyr2245.47, Tyr3116.48,
His3447.39, and Tyr3487.43 decreased the potency and/or
maximum response of orexin-A [14]. A similar study con-
ducted on OX2R discovered that mutations of Thr231
5.46
and Asn3246.55 (corresponding to Thr223 and Asn318 in
OX1R) to alanine led to a 10-fold decrease in orexin-A po-
tency [15]. This indicated that the orexin receptor ligand
binding pocket is lined by residues from TMs 3, 5, 6 and 7
as well as ECL2, which was confirmed by the crystal struc-
ture of OX2R bound to suvorexant [13].
Computational modeling is a powerful tool to gain
insight in the binding of the orexin peptides and the in-
teractions leading to receptor activation. The prospective
GPCR Dock studies [17-19] have shown that the trans-
membrane region of GPCRs can be reliably modeled
and that computational tools are getting better at recreat-
ing receptor–ligand complexes. However, peptide docking
without a known bioactive conformation remains challen-
ging in part due to the inherent flexibility of peptides. In
GPCR Dock 2010, the task of modeling chemokine recep-
tor CXCR4 in complex with a synthetic 16-residue cyclic
peptide proved difficult, since available templates had only
distant homology to CXCR4 and the binding interactions
were poorly characterized [18]. Recently, peptide docking
software such as HADDOCK [20] (originally designed for
protein–protein docking), Rosetta FlexPepDock [21],
and DynaDock [22] have been developed. These soft-
ware were tested with peptides ranging from 2 to 16
residues, often binding into a shallow groove on the
protein surface [20-22]. Buried binding sites and helical
peptides have been problematic [20,21]. Concerning
GPCRs, peptides are docked with multiple methods; a
rigid docking can be followed by a short molecular dy-
namics simulation [23-26], or semi-flexible methods
can be used, such as Glide with induced fit [27] or
GOLD, which allows rotamer-library-based side-chain
rotation for selected residues [28]. Genetic algorithms
can be used to produce changes to peptide backbone
conformation [29]. In this study, we have used ZDOCK
in combination with RDOCK to perform an exhaustive
mapping of the OX1R binding site while allowing limited
peptide and receptor flexibility. ZDOCK and RDOCK
were originally developed for protein–protein docking and
refinement [30,31], but they are also usable in peptide
docking, which became evident in the GPCR Dock 2010
assessment, where one of the best peptide-docking results
came from a group utilizing ZDOCK [18].
Previously, Heifetz and co-workers have aimed to es-
tablish a binding mode for orexin peptides to orexin
Figure 1 Point-mutated residues on the orexin receptors. Orange: mutation impaired the orexin-induced receptor activation in one or both
subtypes; yellow: mutation did not alter the receptor function significantly [14,15].
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served as a template for orexin receptor modeling. To
account for protein flexibility, receptor conformations
for docking were harvested from a short molecular dy-
namics simulation, and certain side chains in both re-
ceptor and ligand were allowed to adopt different
rotamers. However, recent crystal structures for peptide-
binding GPCRs have shown features such as the β-
hairpin in the ECL2 that their models lack, and thus
their results need to be updated.
Here, combining the data from the mutational studies
conducted on orexinergic system and the crystal struc-
tures of peptide-binding GPCRs neurotensin receptor 1
(NTSR1), chemokine receptor CXCR4, and the recent
crystal structure of the OX2R, we have constructed 3D-
models of the OX1R. An exhaustive docking algorithm
allowed mapping of the available space for orexin-A
within the receptor cavity. Based on the molecular inter-
actions observed in the docking results, we propose two
alternative binding modes for orexin-A into OX1R.
Studying these binding interactions will increase the un-
derstanding on the mechanisms by which the orexin
peptides activate their cognate receptors, and provide a
general framework to understand peptide-binding GPCRs.
Methods
Structural alignment of GPCRs
In order to identify structurally conserved regions, we
superposed a total of 19 GPCR crystal structures available
on RCSB Protein Data Bank (PDB) with Discovery Studio
3.5 [32]. Lysozyme chains were removed. A sequence align-
ment was derived from the superposition (Additional files 2
and 3). OX1R sequence was added manually to the align-
ment based on conserved motifs on each transmembrane
helix [33]. We initially based the orexin receptor sequencealignment in the ECL2-region on the observation that all
available crystallized peptide binding GPCRs — chemokine
receptor CXCR4, neurotensin receptor 1 (NTSR1) and the
four opioid receptors (mu, kappa, delta, and nociceptin)
[34-39] — incorporate a similar β-hairpin fold of ECL2,
composed of two five-residue β strands (in OX1R residues
184–188 and 200–204, see arrows in Figure 2 and in
Additional file 2) and a turn of variable length (4–10
residues) between them. For OX2R, this hairpin structure
was confirmed by the crystal structure, although not all
amino acids in the turn were resolved [13]. In the crystal
structures, the first β strand follows directly the TM4 and
the second ranges from xl2.48 to xl2.52. The conserved
disulfide bridge between TM3 and ECL2 constrains the
second β strand, and therefore the β hairpin, above TM3.
Template selection for homology modeling
Based on the structural alignment, the phylogenetic
analysis of GPCRs [40], and the shapes of the observed
binding pockets, we initially selected the crystal structure
of the neurotensin receptor 1 [PDB:4GRV] [35] as a
primary template for homology modeling. At the time,
NTSR1 was the only crystallized receptor from the β
branch of rhodopsin-like GPCRs where orexin receptors
are found [40]. Like orexin receptors, the NTSR1 is also
naturally activated by a peptide ligand, neurotensin.
Neurotensin8–13 fragment has been co-crystallized with
the receptor, but there is no G protein (or an antibody
mimicking it), and thus the receptor conformation is not
fully that of an activated GPCR [35]. While this article was
under review, the crystal structure of OX2R in complex
with the antagonist suvorexant was released [13]. To in-
corporate these recent data into our study, we utilized also
the OX2R crystal structure as a template for homology
modeling.
Figure 2 Sequence alignment used in homology modeling. Target sequence: OX1R [UniProt:O43613]. Template sequences: OX2R [PDB:4S0V],
NTSR1 [PDB:4GRV] and CXCR4 [PDB:3ODU]. Orange: orexin receptor residues found to be important by site-directed mutagenesis. Cyan: NTSR1
residues that interact with neurotensin8-13. Boxed: OX2R residues within 4 Å of suvorexant. Italics: helix 8 from dopamine D3 receptor [PDB:3PBL].
Cylinders and arrows: TM helices and β strands seen in template structures. Numbering refers to OX1R. Triangle: x.50 residue. *: TM3–ECL2 disulfide
bridge. Gray: identical residues between OX1R and templates. Illustrated with Alscript [57].
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constricted by the TM6; the extracellular end of the helix
is tilted towards the binding cavity, narrowing the cavity
and limiting the exposure of the TM5 residues to the
binding cavity. Therefore, we built two secondary hom-
ology models with more open binding cavities. One
secondary model was based on the chemokine receptor
CXCR4 [PDB:3ODU] [34], which naturally binds a small
protein, although the receptor was crystallized with
synthetic ligands. The CXCR4 crystal structure shows a
more open binding cavity than the NTSR1. For the other
secondary model, we constructed a modified NTSR1
structure template (NTSR1_TM6) by rotating the TM6 in
the NTSR1 to occupy the same space as TM6 in CXCR4;
this was done with Maestro 9.3.5 [41].
Neither selected crystal structure shows the 8th helix
parallel to membrane plane observed in many other
GPCR crystals. We selected dopamine D3 receptor
[PDB:3PBL] [42] as a template for the 8th helix. Residues
after Pro7.50 in NTSR1, CXCR4 and NTSR1_TM6 were
replaced by those of dopamine D3 after careful super-
position of TMs 1 and 7 of crystal structures. This was a
cosmetic step that most likely does not affect the docking
results. In retrospect, a more recent X-ray crystal structure
of the NTSR1 [PDB:4BUO] [43] shows an intracellular
assembly with the canonical TM8, as also does the recent
crystal structure of the OX2R [13].Model building
Models of OX1R consisting of the residues Tyr41
1.27–
Gln2465.69 and Arg2916.28–Cys375 were built using the
four templates mentioned above. The N- and C-termini,
and ICL3 were omitted as there were no suitable
templates. Homology modeling was carried out with
MODELLER 9v8 [44], a comparative protein modeling
program, using default settings. Pairwise alignment of
OX1R with the templates was fine-tuned in tandem with
model building (Figure 2). Ten models were derived from
each template structure.Model evaluation
The 40 models were evaluated visually to eliminate
unreasonable constructs and to select four models for
docking, each displaying an open binding cavity and
resulting from a different template. Modeller DOPE
scores did not differ significantly between models of
same origin. We selected the models based on the
conformations of ECL2 and ECL3. The ECL2, especially
the turn between the strands of the β hairpin, was
required to show a secondary structure similar, and
occupying roughly the same space, as those observed in
the crystal structures of peptide binding receptors. The
ECL3 was required not to constrict the entrance of the
binding cavity.
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We used the straight α-helical conformation of orexin-A
(the second NMR model in [PDB:1WSO] [8]) in this
study, as the bent conformation did not fit the predicted
binding site in a preliminary docking. Instead of the full
orexin-A peptide, a fragment comprising of residues
16–33 was used. This fragment retains biological activity
[10], and using it avoids the problem of the N-terminus
of the intact orexin-A colliding with the extracellular
loops of receptor models and limiting the conform-
ational space.
Docking of orexin peptides with ZDOCK and RDOCK
Prior to docking, the receptor models and the peptide
fragment were converted to CHARMm atom types as
required by the docking program. ZDOCK [30], an
exhaustive initial-stage docking algorithm for protein–
protein complexes, was used with default settings. We
filtered the docking poses by accepting only the poses
where the ligand C-terminal residues (shown to be
crucial for activity, see Background) were part of the
receptor–ligand interface and the ligand did not
traverse between the TM helices into the space occupied
by the cell membrane. The poses were refined with
RDOCK [31] using default settings. RDOCK is a
CHARMm force field based refinement algorithm that
performs limited molecular dynamics to fine-tune
receptor–ligand complexes from ZDOCK. RDOCK uses
a two-stage scoring function; van der Waals energy is
first calculated to discard docking poses with clashes
and then the poses are scored based on desolvation
and electrostatic energies. Accelrys Discovery Studio 3.5
[32] was used as an interface to ZDOCK and RDOCK
and to visualize the results.
Data analysis on the docking poses
We clustered the refined docking poses modelwise using
an algorithm devised by Daura and co-workers [45], im-
plemented in MATLAB [46]. In short, a matrix of all
pairwise root mean square deviations (RMSD) of the
peptide α carbons is calculated. The pose with most
neighbors (here RMSD < 3 Å) is flagged as the cluster
seed, and the neighbors are included in the cluster and
removed from the pool of poses. The process is repeated
until no two poses are closer than the cutoff. For cluster
scoring, we used the median RDOCK score of the poses
in each cluster.
For multidimensional scaling, we pooled all docking
poses across models and calculated all pairwise RMSD
values. MATLAB was used to reduce dimensions to two
(mdscale function) and to visualize the outcome. Solvent
accessible surface area for the peptide ligand was calcu-
lated with Naccess [47] (default settings). For measure-
ments of ligand depth, the z-coordinate (z-axis normalto the membrane plane) of the Leu33 α carbon (Cα) was
used. The zero-plane was set to the Cα's of Thr2235.46,
Tyr3116.48 and Tyr3487.43.
We assessed the rotation of the peptide ligand around
its helical axis by drawing a vector towards the side
chain of His26 (from Ala28 Cα to His26 Cα) in xy-plane
(the plane parallel to the membrane). By using a com-
mon initial point for the vectors, preferences in ligand
orientation could be seen.
The contact mapping was carried out with MATLAB
by calculating the pairwise distances between ligand
atoms and atoms in the receptor residues in the binding
cavity. Any pairwise distance between atoms closer than
4 Å was considered a contact. No differentiation be-




The crystal structures of class A (rhodopsin-like)
GPCRs show clear conservation within TM segments
and short loops, as illustrated by the structural align-
ment. The sequence alignment within the TM region is
unambiguous (Additional file 2). The ECL2 and ECL3
vary both in length and in conformation between
receptors, but closely related receptors often show
similarities; for example all peptide binding receptors
(NTSR1, CXCR4, and the four opioid receptors mu,
kappa, delta, and nociceptin, and also the recent OX2R
structure [13,34-39]) show similar β-hairpin structures
in the ECL2, although the segment between the β
strands varies in length: three amino acids in CXCR4,
nociceptin, delta, and mu opioid receptors, five in kappa
opioid receptor, and nine in NTSR1 (see Additional
file 2). The orexin receptors have a segment of 11 amino
acids between the β strands, but five of them were not
solved in the recent OX2R crystal structure. Also ECL3
differs in length among the OX1R and the crystallized
receptors.
Orexin receptors have most class A GPCR-specific
motifs; instead of the conserved Tyr3.51 (in the “DRY”
motif ) and Trp6.48 (at the bottom of the binding cavity,
the “CWxP” motif ), orexin receptors have Trp1453.51
and Tyr3116.48. As both substitutes are aromatic resi-
dues, the structural functions are likely to be conserved.
In the extracellular half of the orexin receptor TM3,
Pro1233.29 is present. This feature is common in the β
branch of rhodopsin-like GPCRs, and a comparison
retrospective to this work between the OX2R structure
and the other crystallized class A GPCRs shows that the
conformation of the TM3 remains unaltered by the
proline.
Templates originally used in this study (NTSR1 and
CXCR4) both have sequence identities of 23.6% (70
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OX1R transmembrane bundle (Tyr41
1.27–Gln2465.69 and
Arg2916.28–Cys375). This level of sequence identity is
usually considered poor for homology modeling, but the
overall fold shared by the crystallized class A GPCRs
was likely to be conserved also in the orexin receptors,
which was confirmed by the OX2R crystal structure
[13]. Within the transmembrane bundle, NTSR1 and
CXCR4 both have six alignment gaps in comparison to
OX1R. For NTSR1, all gaps fall into loops (Figure 2). In
contrast, CXCR4, together with opioid receptors, shows
a gap at 2.57 (2x551 according to the structure-based
residue numbering proposed by the GPCRDB [48]),
which results in the absence of a bulge shown by other
crystallized class A GPCRs. CXCR4 has also a bulge-
inducing insertion at 4.47 (4x471) (Additional file 2),
while other alignment gaps occur in the loops. These
are present in our CXCR4–OX1R sequence alignment
used for homology modeling (Figure 2). As the TMs 2
and 4 are only marginally exposed to the interhelical
cavity, the effect of possible misalignment on the
binding site of the CXCR4-based model is negligible.
Considering the conserved TM3–ECL2 disulfide bridge,
human orexin receptors have two cysteine residues in the
ECL2: Cys185/193 and Cys202/210 (OX1R/OX2R). Based
on the sequence alignment, and the fact that rat OX2R
has arginine instead of Cys193 [UniProt:P56719], we as-
sumed that the Cys202/210 would be involved in the di-
sulfide bridge with Cys119/1273.25. The crystal structure
of OX2R indeed shows the disulfide bridge between
Cys127 and Cys210 (corresponding to Cys119 and Cys202
in OX1R).Homology models
Originally three models were selected, one from each
template, among the 30 generated models. Later a fourth
model, based on the recent OX2R structure, was in-
cluded from a set of ten constructed models (the models
are available as Additional file 4). Overall, the main
chains superimpose well among the models, and in
retrospect also to OX2R crystal structure, but some dif-
ferences arise especially in the loops and in the TM6
(Figure 3, Additional file 5). The side chain conforma-
tions show more variance, but the difference in the back-
bone conformation is more significant to the docking, as
the applied docking protocol is capable of adjusting the
side chains but not the protein backbone.
Our original primary model, based on NTSR1, has a
narrow cavity due to the inward tilt of the TM6 (volume
of ca. 1400 Å3, calculated with 3V-web server [49]). In
retrospect, the overall shape and size of the cavity in the
NTSR1-based model closely resembles that of the
OX2R-based model, which in turn is near-identical inconformation to the OX2R crystal structure (pairwise
heavy atom RMSD 1.07 Å). The ECL2 of the NTSR1-
based model adopts a β-hairpin structure similar to the
OX2R-based model, but the turn between the strands
varies in conformation due to Modeller loop modeling
(Figure 3A). The transmembrane bundle of the NTSR1-
based model superimposes well to the OX2R-based model,
although the side-chain rotamers vary (Figure 3B,C). The
heavy atom RMSD between NTSR1- and OX2R-based
models for binding-site-facing residues is 3.4 Å.
Location of the TM6 is a major difference between the
OX2R-based model and the NTSR1_TM6- and CXCR4-
based models (Additional file 5). Due to the outward-
leaning TM6, the binding cavities of these two models
are more open and spacious (ca. 2000 Å3). Also these
models show the β-hairpin structure in the ECL2
(Additional file 5), and the TMs 2–5 superimpose well
to the OX2R-based model, again with varying side-
chain rotamers. The different conformation of the
TM6 in the NTSR1_TM6- and CXCR4-based models
leads to poor superimposition of binding site residues
over the OX2R-based model. The TM7 is similarly lo-
cated in all models, but in the CXCR4-based model the
TM7 shows a counterclockwise rotation of ~50°
around the helical axis in comparison to the other
models, which slightly alters the set of residues that
face the binding cavity. The heavy atom RMSD of
binding-site-facing residues of the NTSR1_TM6- and
CXCR4-based models in comparison to OX2R-based
model is 4.0 Å and 4.7 Å respectively.
Docking results
Docking into the OX2R-based model produced 1099
docking poses, and to the NTSR1-based model 1164
docking poses. Secondary models based on CXCR4 and
NTSR1_TM6 produced 1180 and 858 poses respectively.
The poses were clustered into 53, 50, 68 and 48 clusters
based on pairwise RMSD.
In the OX2R-based model, the docking poses form a
tight “bouquet” (Figure 4A, Additional file 6), with some
poses leaning over to the TM5-side of the cavity. Top-
scoring clusters occupy a tight space vertically in the
middle of the binding cavity, again with some clusters
leaning over to TM5 (Figure 4B). In the NTSR1-based
model, the available space for the peptide ligand is fan-
shaped (Figure 5A, Additional file 6), which is a result of
the narrow interhelical cavity. The top-scoring clusters
tend to show a vertical ligand orientation with C-
terminus deep in the cavity (Figure 5B). Few clusters
show poses higher and slanted towards TM1.
The more spacious binding cavities of the secondary
models result in wider distributions of docked poses.
The CXCR4-based model has a more open binding site,
which leads to a wide bouquet-like distribution of
Figure 3 Comparison of the homology models. Pink and cyan: OX1R homology models based on OX2R and NTSR1 respectively. Gray: OX2R
crystal structure [PDB:4S0V]. (A) Conformation of ECL2. (B and C) Residues facing the receptor cavity from TMs 1, 5–7 and TMs 2–5 respectively.
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is seen with the ten largest and the top-ten-scoring clus-
ters. However, top-ranking clusters reveal no preferences
in ligand position. For the NTSR1_TM6-based model,
the docking poses fall into two groups; the poses resid-
ing at the TM5-side of the cavity, and the poses leaning
towards the TM1-side of the cavity (Additional file 6).
The ten largest clusters show similar distribution, but
the TM5-side and an upright orientation is favored by
the top-ten-scoring clusters.
Scores for the individual top-scoring poses varied
modelwise. The NTSR1-based model produced the high-
est scores (the best score -17.86), and 35 docking poses
had RDOCK score of -10 or less. The OX2R-based
model produced 11 poses with RDOCK score below -10
(best score -14.47), whereas the NTSR1_TM6 and
CXCR4-based secondary models have 8 and 6 poses withscores < -10, best scores being -12.15 and -11.83 respect-
ively. The narrow binding cavities of the NTSR1- and
OX2R-based models may enable the formation of more
favorable interactions than the secondary models with
more open binding cavities. The average docking pose
scores show only minor differences (-1.50, -1.13 -0.68
and -1.05 for NTSR1-, OX2R-, NTSR1_TM6- and
CXCR4-based models respectively).
RDOCK has originally been designed to refine and
score protein–protein complexes, not docked peptide
ligands. The scoring, however, relies on calculated des-
olvation and electrostatic energies, so it should also be
applicable to peptide docking. In our study, the connec-
tion between the 3D-location of the docking pose and
the score can be seen in the score differences among
clusters, and in the distribution of top-ranked 5 and
10% of the docking poses into clusters (Additional file 7).
Figure 4 3D-representations for the docking pose clusters and scatter plots from multidimensional scaling, OX2R-based model. (A, C) Ten largest
clusters; (B, D) Ten top-scoring clusters. In panels A–B, the TM1 is on the right. Multidimensional scaling shows the clusters (colored; numbers
refer to size ranking) in respect to the pool of docking poses (gray). Poses leaning towards the TMs 1–2 are shown in shades of red/magenta,
poses leaning to the TMs 5–6 are cyan, blue or purple, and poses vertically in the cavity are orange, green or dark green (See Additional file 6 for
all clusters and the color division). The coloring is consistent between 3D-representations and plots.
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differences between the cluster scores are statistically
significant (data not shown). The scoring shows no bias
towards deep ligand binding, as it appears to be uncor-
related with both the solvent accessibility of the peptide
ligand and the depth of binding (Additional file 7). There-
fore it appears reasonable to focus further analysis on the
top-ranking individual poses.
Top-ranking poses
For each model, top-ranking poses were selected for
closer examination. For the NTSR1-based model, the 35
docking poses that had RDOCK score of -10 or lower
were used. As the top-scores for the other models were in
general worse, a filter of RDOCK score < -8 was applied toyield 29, 38 and 29 docking poses from the OX2R-,
CXCR4- and NTSR1_TM6-based models respectively. In
all four models, the majority of top-ranking poses show
the peptide ligand about vertically fairly deep in the bind-
ing cavity (Figure 6). The NTSR1-based model shows
ligand depth of 3.7–9.9 Å (median 6.1 Å, zero-level at
Tyr3116.48 Cα, see Methods), whereas the OX2R-based
model favors deeper binding (median 5.0 Å, 2.8–14.7 Å).
Regarding the secondary models, the best poses from the
NTSR1_TM6-based model are more diverse, and depths
range from 2.9 Å to 16.6 Å (median 5.5 Å). The best dock-
ing poses from the CXCR4-based model are a bit higher,
5.5–11.4 Å (median 8.8 Å).
The rotational orientation was assessed as the direc-
tion of bulky residues close to C-terminus (His26,
Figure 5 3D-representations for the docking pose clusters and scatter plots from multidimensional scaling, NTSR1-based model. (A, C) Ten largest
clusters; (B, D) Ten top-scoring clusters. The view and color coding is as in Figure 4.
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In each model, definite preferences are seen, although
these preferences are not the same for all models. In the
top-ranking poses from the NTSR1-based model and
the NTSR1_TM6-based secondary model, the bulky resi-
dues face the TM5-side of the cavity in 70% of the poses.
For the remaining top-scoring poses, the bulky residues
face TM7. The preferences in the NTSR1_TM6-based
model are not as strict as in the NTSR1-based model.
The OX2R-based model also shows these two groups of
docking poses, but the preference is reversed; the major-
ity of the top-ranking poses (69%) shows the bulky lig-
and residues facing the TM7, whereas the TM5-facing
poses are a minority (24%). The docking poses in the
CXCR4-based secondary model have a different prefer-
ence, where the majority of the poses has the bulky resi-
dues on the TM1-side of the cavity, or facing towards
TM2–3-side of the receptor. This difference in the pre-
ferred orientation is not surprising, given that the dockingposes in CXCR4-based model are in average ~2 Å closer
to extracellular surface and thus have access to different
areas of the binding cavity. This is likely caused by the
bulky residues of TM7, especially His3447.39, which in the
CXCR4-based model face the cavity more prominently
due to the 50° counterclockwise rotation of the TM7.
These modelwise preferences in orientation are clearly
mirrored in the mapping of contact frequencies between
ligand and receptor residues (Additional file 8).
Two alternative binding modes
The top-ranking docking poses from the OX2R- and
NTSR1-based models were divided into two categories
based on the peptide rotational state. The binding mode
with TM5-facing bulky residues (“TM5-mode”) was
adopted by 31 poses (7 + 24 poses from the OX2R- and
NTSR1-based models respectively), whereas 30 poses
(20 + 10) show the bulky residues towards the TM7
(“TM7-mode”). The OX2R-based model shows two
A B C D
Figure 6 Modelwise depth and orientation of top-ranking docking poses. (A) OX2R-based model, (B) NTSR1-based model, (C) NTSR1_TM6-based
model, (D) CXCR4-based model. Direction of His26 side chain plotted with arrows, as seen from the extracellular side. For vertical peptides the
arrows touch the inner circle, for tilted peptides the arrows are shorter. Scatter plots show RDOCK score as a function of binding depth. Poses
below the filter threshold are shown in red.
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the NTSR1-based model shows one (Figure 6).
In both binding modes, the peptide C-terminus lies
deep in the interhelical pocket, and forms reasonable in-
teractions that take advantage of important amino acids
(discussed in detail below). In the peptide N-terminus,
the TM5-mode shows apparent better complementarity
of hydrophobic and hydrophilic residues between the
peptide and the receptor than the TM7-mode (Figure 7).
Especially the hydrophobic amino acids in the peptide
N-terminus (L16, L19, and L20) make a drastic differ-
ence between the binding modes. The TM5-mode shows
these amino acids close to the ECL2 hairpin, partially
shielded from the solvent (Figure 7B), whereas in the
TM7-mode these amino acids are exposed to the solvent
(Figure 7D). This exposure would remain the same with
full orexin-A peptide as the disulfide-bridge-stabilized
N-terminus lies on the opposite side of the peptide than
the hydrophobic group of L16, L19 and L20 (Figure 7A).
However, our models lack the receptor N-terminus, and
both the conformation of the turn structure in the
receptor ECL2 hairpin and the ligand N-terminus could
be different. These factors could have extensive effect on
the solvent exposure of hydrophobic ligand residues.
Both binding modes appear to be compatible with
full-length orexin-A. The disulfide-bridge-stabilized N-
terminus of orexin-A in the straight conformation wouldbe close above ECL3 in the TM5-mode, whereas in the
TM7-mode it would be near the hairpin-turn of the
ECL2. In contrast, the bent conformation, which is more
frequently seen in the solution NMR-studies, would not
fit these binding modes, as the peptide N-terminus
would clash into TM7 or receptor N-terminus in the
case of the TM5-mode and into the ECL2 for the TM7-
mode.
Binding interactions
For both binding modes, a representative pose was se-
lected to illustrate binding interaction at the atomic level
(Figures 8 and 9). The interactions are summarized in
Table 1. In general, orexin-A presents two large hydro-
phobic surfaces, one close to each terminus. The polar
side chains, the peptide backbone at the flexible hinge
region and, at the last helical turn, the exposed carbonyls
and the amidated C-terminus offer sites for hydrogen
bonding and electrostatic interactions.
We compared orexin-A C-terminal interactions to
suvorexant binding in the OX2R crystal structure [13].
Suvorexant binds deep in the cavity with multiple hydro-
phobic interactions, while the triazole ring is sandwiched
within hydrogen-bonding distance between Gln3.32 and
Asn6.55 and the amide carbonyl could hydrogen bond to
Asn6.55 and His7.39 (water-mediated) (Figure 10B). This
binding mode does not disturb intramolecular receptor
Figure 7 Orexin-A peptide and the surface complementarity of the two binding modes. (A) Orexin-A from opposite sides. (B, C) TM5-mode.
(D, E) TM7-mode. Panels B and D show hydrophobic, and panels C and E hydrophilic surfaces. Receptor surfaces on color scale brown-blue
(hydrophobic-hydrophilic), ligand surfaces magenta-green. The receptor surface has been drawn based on the side chain atoms of the residues
that have atoms within 4 Å of the peptide ligand.
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Arg6.59, Gluxl2.52–His5.39 and Asp2.65–His7.39.
In our TM7-binding mode, the ligand C-terminus
closely follows the hydrogen bonding of suvorexant to
Asn6.55 and Gln3.32 (Figure 10A). The TM7-mode also
features His26 close to receptor His3447.39 and
Asp1072.65, which is especially interesting in the light of
recent results suggesting that orexin-A binding to OX1R
is calcium-dependent [50], as histidine/aspartic acid
clusters are known to participate in the hexadentate co-
ordination of metal ions. The ligand Leu31 is close
enough to break the His2165.39–Glu204xl2.52 salt bridge.
Flexibility and small side chains at the peptide hinge re-
gion would permit hydrogen bonds from Asp203xl2.51
and Arg3226.59 to the peptide backbone. The phenolic
oxygen in the Tyr3116.48 lies 4.8 Å away from the C-
terminal carbonyl, but could reach hydrogen bonding
distance with a different rotamer. In other GPCRs, the
corresponding Trp6.48 is often thought as a key residue
for receptor activation.
The TM5-mode, on the other hand, does not replicate
the suvorexant hydrogen-bonding pattern (Figure 10C).
However, it displays hydrogen bonding to receptor
Gln1263.32 (ligand T32 carbonyl or C-terminus) and thepeptide C-terminus often comes close enough to hydro-
gen bond to Tyr3116.48 (roughly half of the top-ranking
poses that adopt the TM5-mode show Tyr3116.48 within
4 Å, but the representative pose in Figure 9 does not).
The ligand His26 is close to His2165.39 and Glu204xl2.52,
which could serve as a metal binding site as well, and
again the hinge region offers hydrogen-bonding sites for
Asp203xl2.51 and Arg3226.59.
These interactions are reminiscent of the activation
determinants of other GPCRs. Adrenoceptors, for ex-
ample, show an active state where the binding site con-
traction is stabilized by ligand binding between the
transmembrane helices, namely hydrogen bonding to
Asp3.32, Ser5.42, Ser5.46 and Asn7.39 [51-53]. However,
even though our binding modes show the orexin peptide
deeper than neurotensin in NTSR1, the peptide does not
fully reach the depth of the adrenoceptor agonists. Con-
tacts to Phe2195.42 are formed by Leu31 in the TM7-
mode, and Leu33 in the TM5-mode, but only in few
poses within the more open binding cavity of the
NTSR1_TM6-based model, the orexin peptide pene-
trates deep enough to bind to Thr2235.46.
Closer to the extracellular surface, the orexin peptide
forms interactions which are more like those seen
Figure 8 The TM7-binding mode. (Top left) Overview of receptor–ligand interactions. (Top right) Heatmap shows preferred peptide–receptor
interactions (interatomic distance < 4 Å) within the high-scoring poses that adopt this binding mode. X: observed in the representative pose.
(Bottom) A cross-eyed stereogram. Orange: hydrogen bond, red: salt bridge or charge-assisted hydrogen bond, blue: CH–O hydrogen bond,
magenta: lone pair-π, black: hydrophobic.
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residues in the TM7-mode interact with the receptor N-
terminus and extracellular loops 1 and 3 (Glu18 with
Lys431.29 and Arg3337.28, His21 with Glu1102.68, Asn25
with Cys202xl2.50, and His26 with Asp1072.65), whereas
in the TM5-mode interaction to the ECL2 and ECL3
take place (His26 to Glu204xl2.52, Asn25 to Lys3216.58 and
Tyr3377.32, and His21 to Lys3216.58 and to Arg3337.28 or
Arg3286.65). These interactions put together could change
the binding site conformation and result in the activation
of the receptor.Comparison to the receptor point mutations and
neurotensin binding
The point-mutation studies on orexin receptors have indi-
cated residues Gln1263.32, Val1303.36, Asp203xl2.51,
Trp206xl2.54, Tyr2155.38, Phe2195.42, Thr2235.46, Tyr2245.47,
Tyr3116.48, Asn3186.55, His3447.39 and Tyr3487.43 to be
relevant for the orexin-peptide-triggered receptor activa-
tion (see Background). Of these residues, we already dis-
cussed Gln1263.32, Asp203xl2.51, Phe2195.42, Thr2235.46,
Tyr3116.48, Asn3186.55 and His3447.39 above. Concerning
the remaining amino acids, the TM7 binding mode was
Figure 9 The TM5-binding mode. Overview of receptor–ligand interactions. (Top right) Heatmap shows preferred peptide–receptor interactions
(interatomic distance < 4 Å) within the high-scoring poses that adopt this binding mode. X: observed in the representative pose. (Bottom) A
cross-eyed stereogram. Color coding as in Figure 8, but magenta marks cation-π interaction.
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(Figure 8, Table 1). The side chain of Trp206xl2.54 lies
between TMs 4 and 5, lining the binding cavity, but a
different rotamer could bring the side chain closer to
the ligand. The side chain of Tyr2245.47 lies between
TMs 5 and 6 in all models, where it is not exposed to
the ligand. Val1303.36 at the bottom of the binding cav-
ity is often within 4 Å of the peptide ligand C-terminus.
In total, the TM7-mode shows interactions to eight of
these residues, whereas the TM5-mode interacts with five.
Residues at the bottom of the binding cavity
(Val1303.36, Thr2235.46, Tyr3116.48 and Tyr3487.43) are
difficult for the ligand to reach in our models. Water
molecules are often seen to take part in ligand–receptorinteractions, but the applied docking protocol handles
water implicitly, so water molecule mediated interactions
cannot be addressed. It is also noteworthy that site-
directed mutagenesis is an indirect method, and that the
indicated residues might not take part directly in the lig-
and binding, but are part of the receptor activation cas-
cade, or otherwise crucial for the receptor function.
The data from mutation studies was used to direct our
docking efforts towards the binding site formed both by
the cavity between TM helices and by the loops. This
approach has proven effective in the case of neurotensin
receptor 1, where extensive mutation and modeling
studies had predicted that neurotensin would interact
mainly with the ECL3 and upper parts of TMs 6 and 7
Table 1 Binding interactions of the two presented binding modes
Ligand
residue
Interactions with receptor residues
TM7-mode TM5-mode
Leu16 Alkyl - Val188xl2.36, Glu191xl2.39 -
Tyr17 Aromatic - Phe199xl2.47 Alkyl-π - Met3266.63
Glu18 Salt bridge - Arg3337.28, Lys431.29 Salt bridge - Arg3226.59
H-bond - Tyr411.27 (backbone N)
Leu19 CH–O to backbone - Arg3337.28 -
Leu20 - -
His21 Aromatic - Phe199xl2.47 H-bond - Arg3337.28
Alkyl-π - Val201xl2.49 Cation-π - Arg3286.65
H-bond - Glu1102.68 (backbone carbonyl) Alkyl-π - Met3266.63
H-bond to backbone - Arg3226.59
Gly22 - -
Ala23 Alkyl - Arg3337.28 Alkyl - Arg205xl2.53
H-bond to backbone - Lys3216.58
Gly24 - CH–O hydrogen bond - Asp203xl2.51
Asn25 H-bond - Cys202xl2.50 (backbone nitrogen) H-bond - Arg3286.65, Lys3216.58 (putative)
H-bond to backbone - Glu204xl2.52, Lys3216.58 (conventional or CH–O)
His26 Aromatic - Tyr3377.32, Phe3407.35 Alkyl-π - Arg3226.59, Val1824.63, Pro2125.35
CH–O hydrogen bond - Asp1072.65 H-bond - Glu204xl2.52
CH–O hydrogen bond - Pro2125.35 (carbonyl)
Ala27 Alkyl - Lys3216.58 Alkyl - Met1834.64
Ala28 Alkyl - Met1834.64 -
H-bond to backbone - Asp203xl2.51
Gly29 - H-bond to backbone - Asn3186.55 (requires rotamer change)
Ile30 Alkyl-π - Phe3407.35, His3447.39 Alkyl - Pro1233.29
Alkyl - Ile3146.51, Ser3237.38 H-bond to backbone - Gln1263.32
H-bond to backbone - Asn3186.55
Leu31 Alkyl-π - Tyr2155.37, His2165.39 Alkyl-π - Trp112xl1.50
Lone pair-π from backbone - Phe2195.42 Alky - Ile1223.28, Pro1233.29
H-bond to backbone - Ser1032.61
CH–O hydrogen bond to backbone - His3447.39
Thr32 H-bond - Gln1794.60, Pro1233.29 (backbone carbonyl) Alkyl-π - Phe3407.35, His3447.39
Alkyl - Ile3146.51
H-bond - Ser3437.38, His3447.39 (either to threonine hydroxyl or
backbone carbonyl)
Leu33 Alkyl-π - His3447.39, Tyr3487.43 Alkyl-π - Phe2195.42
Alkyl - Ile3146.51, Val3477.42 Alkyl - Ile3146.51
H-bond to backbone - Gln1263.32
NH2 H-bond - Tyr3116.48 (requires rotamer change) Close to Gln1263.32 (unfavorable geometry for H-bond)
Interactions divided by type. Unless otherwise noted, the interacting atoms are side-chain atoms. “Requires rotamer change” denotes putative interactions which
would take place if a receptor residue adopted a slightly different rotamer. Receptor residues whose mutation has been shown to be detrimental to orexin peptide
binding are in bold.
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line with this prediction [35]. It shows the neurotensin8–13
binding in a way consistent with the mutationexperiments, fairly high in the cavity (neurotensin8–13
Leu13 Cα is ~12 Å above Tyr3597.43 Cα). The orexin
peptides, however, are considerably larger than
Figure 10 Comparison to suvorexant binding. (A and C) TM7- and TM5-modes respectively, (B) Suvorexant binding. Orange dash: hydrogen
bond. Only a subset of binding interactions is shown for clarity. Viewpoint from TM7.
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ing and different interacting residues on the receptor
(Figure 3). It is noteworthy that homologous binding-
site-facing residues are often smaller in orexin recep-
tors than in NTSR1, permitting the entry of a larger lig-
and. Changes such as Tyr3.29 to proline, Arg3.32 to
glutamine, Tyr6.51 to isoleucine, and Arg6.55 to aspara-
gine create a more spacious binding cavity in OX1R
than observed in NTSR1.
Unfortunately, the mutation studies on the orexin re-
ceptors are not as extensive as on the neurotensin recep-
tor 1. Point mutations on orexin receptors have been
focused on the residues deep in the cavity, with the ex-
ception of few ECL2 residues, whereas the ECL3 has so
far been neglected. In addition, in the mutation studies
only few residues are reported not to be important, mak-
ing mutation based comparison and validation of bind-
ing modes more difficult.Conclusions
In this work, we present two alternative binding modes
for orexin-A to OX1R, each with their own merits. The
receptor models, based on the framework of the neuro-
tensin receptor 1 and the orexin 2 receptor, which was
published while this work was under consideration, pro-
vide accurate representations of the transmembrane
bundle, and the conformation of the extracellular do-
main. Our docking protocol allows for side chain move-
ments, which should smooth out small-scale inaccuracies
in the conformation. The binding modes are consistent
with what is known of GPCR activation in general, and fit
well to the mutational data. The available mutation data
only partially covers the predicted binding site, but we
hope our work will direct further mutation studies, espe-
cially towards the ECL3. Due to the high sequence identitybetween the orexin receptor subtypes and similarity of the
peptide C-termini, these results should also be transfer-
able to OX2R and orexin-B. These alternative binding
modes for the orexin-A into OX1R, produced by compu-
tational modeling and docking, should benefit further
characterization of orexin receptor interactions and thera-
peutic small molecule discovery.Endnote
aResidues in the transmembrane helices are numbered
according to Ballesteros and Weinstein [33]. The most
conserved residue of each transmembrane helix is de-
fined as N.50 where N is the ordinal number of the helix
counting from the N-terminus. Residues in the ECL2 are
numbered similarly so that the bridge-forming cysteine
is designated as xl2.50 [56]. In addition, the structure-
based residue numbering proposed by the GPCRDB is
used when there are differences in the bulges or con-
strictions within the helices [48].Additional files
Additional file 1: The conformations of orexin peptides in aqueous
solution. Orexin-A has been reported with multiple conformations that
fall into two categories; a bent conformation and a straight conformation.
For orexin-B, one conformation has been reported.
Additional file 2: Structural alignment of crystallized class A GPCRs,
and the sequence alignment of human OX1R.
Additional file 3: The structural alignment from Additional file 2, in
FASTA format. Chain breaks have not been annotated.
Additional file 4: PDB-file of the OX1R homology models together
with the representative docking poses for the models. 1: OX2R-based
model, 2: NTSR1-based model, 3: CXCR4-based model, 4: NTSR1_TM6-
based model.
Additional file 5: Comparison of the secondary models to the OX2R
crystal structure. Corresponds to Figure 2, but shows the CXCR4- and
NTSR1-based models.
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Additional figure 6.1: 3D-representations for all docking pose clusters
modelwise. AF6.2, AF6.3: Docking pose clusters in the CXCR4- and
NTSR1_TM6-based secondary models, corresponding to Figures 4 and 5.
AF6.4: Superclustering across models.
Additional file 7: Statistics for the docking poses, modelwise. Five
plots are shown for each model. 1) A box plot of RDOCK score vs. clusters;
2) Scatter plot of RDOCK score vs. ligand depth; 3) Scatter plot of RDOCK
score vs. ligand solvent accessible surface area; 4) Scatter plot of ligand
solvent accessible surface area vs. ligand depth; and 5) Distribution of high-
scoring poses into clusters.
Additional file 8: Representative docking poses and interaction
heatmaps, modelwise. Additional figures corresponding to Figures 8
and 9, but for all top-scoring docking poses for each model. Addition
figure 8.1 shows the representative high-scoring pose for the OX2R-based
model, AF8.2 for the NTSR1-based model, AF8.3 for the CXCR4-based
model, and AF8.4 for the NTSR1_TM6-based model.
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